AD-LIB.IO
12.5.2021 09:02:04 CEST | Business Wire | Press release
Ad-Lib.io , the next-generation Creative Management Platform for marketers at the world’s largest brands, today announced that it has been certified as a Google Marketing Platform (GMP) Partner in Spain, bringing Ad-Lib.io its sixth creative certification as it continues to extend its footprint across the globe.
The GMP Creative Certification in Spain affirms that Ad-Lib.io has demonstrated the ability to work within Google’s best practices and technology, and reinforces that its next-generation Creative Management Platform upholds high standards of service for creative design and process management. The certification reaffirms Ad-Lib.io’s successful client track record and its expertise across key capabilities including coding, asset delivery, and client services. The certification gives Ad-Lib.io , early access to product releases and announcements, and to a variety of other Google program resources.
“As the advertising industry emerges from a difficult year, advertisers are pushed to make their creative workflow more efficient while ensuring their ads stand out and perform well,” said Adit Abhyankar, CEO of Ad-Lib.io. “As a Google Marketing Platform Partner certified on the Creative tools, Ad-Lib.io offers advertisers in Spain on Google’s tech stack, the ability to easily and quickly build and activate content at scale, across formats and channels. Ad-Lib.io has been a trusted Google Partner since our founding in 2017 and we will continue to lead the way for advertisers that seek to produce and optimize relevant creative at scale.”
“As Google and its customers continue to find new ways to work together, partners like Ad-Lib.io are an important part of our ecosystem as they got certified.” according to Jose Maria Perez Sastre, Partnerships Manager at Google. “We are pleased that Ad-Lib.io continues to grow its presence and customers in Spain. We have seen great success already working together on clients in the region and we look forward to the continuing partnership in Spain and in other markets around the globe.”
This milestone strengthens Ad-Lib.io’s capability for customers working with the Google Marketing Platform in Spain and globally, as marketers seek solution providers that operate in the markets they serve. One partner with multi-region certifications, Ad-Lib.io is also a GMP Creative Partner in the United Kingdom, the United States, Dubai, Australia and Singapore.
“I'm very excited by the launch of another Google-certified market in Spain!” said Oli Marlow Thomas, founder of Ad-Lib.io. “This accompanies the awesome news that Ad-Lib.io DE is now up and running with former Googler Felix Derkum leading the charge. Ad-Lib.io is pushing into all parts of Europe.”
For more information about Ad-Lib.io, please visit: https://www.ad-lib.io/ .
About Ad-Lib.io
Ad-Lib.io provides the leading next-generation Creative Management Platform for marketers at the world’s largest brands to enable them to scale their digital creative. Ad-Lib.io connects creative and media workflows using intelligent automation, making it easy and fast to produce and optimize relevant ad creative across all digital channels. These ads are 60% more cost-efficient to produce, according to Ad-Lib.io’s customers which include 10 of the top 30 global brands. The venture-backed company -- recognized as a 2021 Start Up of the Year by Campaign Magazine -- was founded by former Google executives who understood the need to close the wide gap between creative concepts and digital media execution. Ad-Lib.io is headquartered in London, UK with offices in North America, Asia, Australia, Europe and the Middle East.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005183/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom